# Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

> **NCT02070549** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Malignant Solid Neoplasm
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02070549
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-10
- **Primary completion:** 2024-12-18
- **Final completion:** 2024-12-18
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070549, "Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02070549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*